# Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

> **NCT04235205** · PHASE2 · COMPLETED · sponsor: **Yokohama City University** · enrollment: 102 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- **DRUG:** Elobixibat 10mg + cholestyramine powder placebo
- **DRUG:** Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)
- **DRUG:** Elobixibat placebo + cholestyramine powder placebo

## Key facts

- **NCT ID:** NCT04235205
- **Lead sponsor:** Yokohama City University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-29
- **Primary completion:** 2021-07-21
- **Final completion:** 2021-09-30
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04235205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04235205, "Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04235205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*